OIG Advisory Opinion: 24-04

    Favorable

    Refunds + price protection discounts on ultra-rare one-time therapy

    Recorded opinion date:

    The commentary below transcribes Cabra's existing summary PDF. It preserves the original analysis, including its checklist and wording. The original PDF remains available below. Advisory opinions concern their particular facts and requestors; this commentary is not legal advice.

    What OIG Said

    OIG said this structure avoids kickback risk if pricing terms are clearly scoped, pre-approved, and documented, and if risk shifts aren’t used to steer volume.

    ✓Requestor offered two financial protections to a treatment center for a one-time, high-cost drug: (1) a full refund or waiver if payers deny coverage, and (2) a price-lock discount if WAC increases after the insurer signs off but before the drug is delivered.

    ✓OIG said this counts as remuneration, but allowed it due to tight constraints: small patient universe, required pre- approval from insurers, and no marketing to referring physicians or patients.

    ✓The structure was backed by advance insurer contracts, documentation of pricing terms, and transparency in invoices and cost reports, all of which reduced fraud risk.

    ✓OIG highlighted that commercial necessity (not patient steerage) drove the refund offer, and that the discount met safe harbor conditions, including arms-length terms and appropriate cost reporting.

    Diligence Checklist

    What you need to be ready to show in diligence

    ✓Show full documentation of any refund, waiver, or price adjustment logic, including insurer pre-approval, contracts, and patient coverage status.

    ✓Prove that refund terms are not tied to volume or referrals, and that they are applied consistently regardless of payer type.

    ✓Maintain evidence that cost reporting and invoicing reflect the true economic impact of any refund or discount.

    ✓Confirm the structure is commercially necessary, not just a way to shift risk and capture volume.

    ✓Document that pricing terms (including WAC lock-ins) are negotiated at arms length and apply uniformly across payors.

    If you can’t defend your refund and discount mechanics as commercially necessary, pre-approved, and FMV- aligned, OIG says that’s the profile they will scrutinize.

    Structure not diligence-ready?

    Cabra Consulting helps healthcare organizations make sure compensation and transaction structures are independently valued, clearly scoped, and defensible in diligence.

    Original PDF cover text

    FAVORABLE

    OIG WATCH 24-04

    Refunds + price protection discounts on ultra-rare one-time therapy

    Cabra commentary publication date is not recorded in the existing source. No publication or revision date has been inferred from this HTML conversion.

    Source documents

    Preparing document preview…

    Ready to Move Forward?

    Let's explore how we can support your goals